Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2005 Jan;131(1):60-6.
doi: 10.1007/s00432-004-0625-0. Epub 2004 Sep 22.

The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain

Knut Liepe  1 , Roswitha Runge, Jörg Kotzerke
Affiliations
Clinical Trial

The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain

Knut Liepe et al. J Cancer Res Clin Oncol. 2005 Jan.

Abstract

Purpose: The surface bone-seeking radiopharmaceuticals rhenium-188-HEDP (188Re-HEDP) and samarium-153-EDTMP (153Sm-EDTMP) were investigated to determine the efficacy and toxicity in pain palliation in bone metastases.

Method: The effect of treatment with 188Re-HEDP and 153Sm-EDTMP on pain symptoms, life quality, and bone marrow function were obtained in 46 patients with prostate and breast cancer. There were 31 patients treated with 188Re-HEDP (3194+/-387 MBq) and 15 patients with 153Sm-EDTMP (2940+/-545 MBq). The 188Re-HEDP group included 6 patients and 25 patients, and the 153Sm-EDTMP group 6 patients and 9 patients with breast and prostate cancer, respectively. All patients had an interview using standardized sets of questions before and after therapy for 12 weeks. Blood counts were taken weekly for 6 weeks and after 12 weeks.

Results: After treatment with 188Re-HEDP, 77% of patients reported pain relief and 73% after 153Sm-EDTMP. Sixteen percent of the patients treated with 188Re-HEDP and 13% of those given 153Sm-EDTMP could discontinue their analgesics and were pain free. Patients described an improvement on the Karnofsky performance scale from 73+/-7 to 85+/-8% 12 weeks after 188Re-HEDP (p<0.05) and from 68+/-9 to 74+/-9% after 153Sm-EDTMP (p=0.217). Only 3 patients post-188Re-HEDP and 2 patients post-153Sm-EDTMP showed a thrombocytopenia below 100 x 10(3)/microl. The maximum nadir of platelet and leukocyte counts were observed between the second to fourth week after treatment in both and was reversible within 12 weeks. There were no significant differences in pain palliation, Karnofsky performance scale and bone marrow toxicity between the lower beta energy 153Sm-EDTMP and the higher beta energy 188Re-HEDP (p=0.098-0.442).

Conclusion: Both radiopharmaceuticals were effective in pain palliation, without induction of severe side effects or significant differences in therapeutic efficacy or toxicity.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Time course of the Karnofsky performance scale before and within 12 weeks in all 31 patients with 188Re-HEDP therapy (with standard deviations)
Fig. 2
Fig. 2
Time course of the Karnofsky performance scale before and within 12 weeks in all 15 patients with 153Sm-EDTMP therapy (with standard deviations)
Fig. 3
Fig. 3
Time course of the pain at visual analog scale before and within 12 weeks in all 31 patients with 188Re-HEDP therapy (with standard deviations)
Fig. 4
Fig. 4
Time course of the pain at visual analog scale before and within 12 weeks in all 15 patients with 153Sm-EDTMP therapy (with standard deviations)
Fig. 5
Fig. 5
Bone marrow impairment due to 188Re-HEDP expressed as platelet counts in serial blood samples in all 31 patients (with standard deviations)
Fig. 6
Fig. 6
Bone marrow impairment due to 153Sm-EDTMP expressed as platelet counts in serial blood samples in all 15 patients (with standard deviations)
Fig. 7
Fig. 7
Bone marrow impairment due to 188Re-HEDP expressed as leukocyte counts in serial blood samples in all 31 patients (with standard deviations)
Fig. 8
Fig. 8
Bone marrow impairment due to 153Sm-EDTMP expressed as leukocyte counts in serial blood samples in all 15 patients (with standard deviations)
See this image and copyright information in PMC

References

    1. Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Cabahug CJ, D’Alessandro T (1995) Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: a pilot study. J Nucl Med 36:725–729 - PubMed
    1. Bishayee A, Rao DV, Srivastava SC, Bouchet LG, Bolch WE, Howell RW (2000) Marrow-sparing effects of 117mSn(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer. J Nucl Med 41:2043–2050 - PubMed
    1. Blower PJ, Kettle AG, O’Doherty MJ, Coakley AJ, Knapp FF Jr (2000) 99mTc(V)DMSA quantitatively predicts 188Re(V)DMSA distribution in patients with prostate cancer metastatic to bone. Eur J Nucl Med 27:1405–1409 - PubMed
    1. Breen SL, Battista JJ (2000) Cavity theory applied to the dosimetry of systemic radiotherapy of bone metastases. Phys Med Biol 45:879–896. - PubMed
    1. Caraceni A, Cherny N, Fainsinger R, Kaasa S, Poulain P, Radbruch L, De Conno F (2002) Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 23:239–255 - PubMed

Publication types

MeSH terms